Supplement Scholar
GH Secretagogue / Cachexia

Anamorelin

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

Anamorelin. Oral ghrelin agonist developed for cancer-related cachexia and appetite loss.

How it works. Mimics ghrelin to stimulate appetite, lean body mass, and GH/IGF-1 axis in catabolic states.

What the research supports. 2 graded claims. Strongest: Oral dosing (preclinical).

Hormonal impact. Effects on GH, IGF-1, Ghrelin signaling.

Side effects and interactions. 1 medication interaction listed. Serious: Cardiac conduction concerns in early trials, not a major label signal.

Stacking. Pairs well with Nutritional support and resistance exercise as tolerated. Avoid combining with Uncontrolled diabetes.

Common forms. Available as Oral tablet.

Community. Experiences from people who have tried Anamorelin. Anecdotes are not medical advice.

Anamorelin. Oral ghrelin agonist developed for cancer-related cachexia and appetite loss.

Molecular structureC31H42N6O3 · 546.7 g/mol

What it is

Anamorelin is an orally active ghrelin receptor agonist developed for cancer cachexia, approved in Japan for non-small-cell lung cancer cachexia.

Also called

ONO-7643

How it works

Mimics ghrelin to stimulate appetite, lean body mass, and GH/IGF-1 axis in catabolic states.

Pathways

  • GHSR-1a
  • GH and IGF-1 axis
  • Appetite regulation

Effects

  • ↑Lean body mass in cancer cachexia increases
  • ↑Appetite increases

What the research supports

Oral dosingpreclinical
Combined appetite and anabolic mechanismpreclinical

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Hormonal impact

↑GHincreases
↑IGF-1increases
↑Ghrelin signalingincreases

Side effects & interactions

Common side effects

  • Hyperglycemia
  • Diabetes diagnosis or worsening

Serious

  • Cardiac conduction concerns in early trials, not a major label signal

Medication interactions

CYP3A4 inhibitorsmoderate

Increased anamorelin exposure.

Check any supplement–medication combination with your pharmacist before starting.

Combines with

Pairs well

  • Nutritional support and resistance exercise as toleratedMaximizes lean-mass response.

Avoid combining

  • Uncontrolled diabetesMay worsen glycemic control.

Common forms

  • Oral tablet

Discussion

Loading discussion…